Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People.
Level 5 - mechanism / opinion, no new human data
Expert consensus statement and practice guideline based on literature review without original human data or systematic review methodology reported.
PubMed 20392703 · doi:10.1093/ageing/afq034
What was done
The European Working Group on Sarcopenia in Older People (EWGSOP), representing four European and international geriatric and nutrition societies, reviewed the literature to establish clinical definitions, diagnostic criteria, cut-off points, and an assessment algorithm for age-related sarcopenia.
What was found
The abstract reports no numerical trial findings or statistical effect sizes. The panel defined sarcopenia as the presence of both low muscle mass and low muscle function (strength or performance). It established three conceptual stages—presarcopenia, sarcopenia, and severe sarcopenia—and proposed a clinical case-finding algorithm based on gait speed, grip strength, and muscle mass.
Why it matters
This landmark consensus statement established a standardized operational definition and staging framework for sarcopenia to guide clinical geriatric assessment and research outcome measures.
Limits
The abstract describes an expert consensus guideline rather than primary empirical data or a formal systematic review. Quantitative diagnostic accuracy metrics (sensitivity, specificity) and specific numerical cut-offs are not detailed in the abstract.
Cited by
- context After age 50, muscle mass loss accelerates to 1% to 2% per year, totaling 10% to 14% loss per decade.